NCT05572996Available不适用
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient consent
- •Males and females aged 18 years old or older
- •PH-ILD diagnosis:
- •Confirmed diagnosis of Group 3 PH by Right Heart Catheterization (RHC):
- •mPAP > 20 mmHg with PAWP ≤ 15 mmHg and PVR ≥ 2 WU and
- •Confirmed diagnosis of diffuse parenchymal lung disease based on imaging (any form of ILD or CPFE)
排除标准
- •Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD
- •Use of concomitant PAH drugs contraindicated for PH-ILD (ambrisentan and riociguat)
- •Use of any concomitant investigational drug
研究者
相似试验
No Longer Available
不适用
Expanded Access to Rovalpituzumab TesirineSmall Cell Lung CancerNCT03503890AbbVie
Temporarily Not Available
不适用
Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)NCT04830202AbbVie
Available
不适用
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNCT04159597AbbVie
No Longer Available
不适用
Expanded Access to Bimatoprost (Durysta)Open-angle GlaucomaNCT05338606AbbVie
招募中
3 期
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionHypertension, PulmonaryNCT05179876Actelion280